<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03774732</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0107/1718</org_study_id>
    <nct_id>NCT03774732</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer</brief_title>
  <acronym>NIRVANA-LUNG</acronym>
  <official_title>PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer&#xD;
      (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in&#xD;
      non squamous NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death&#xD;
      1/ligand 1 (PD-1/-L1) were targeted with nivolumab (IgG4) in advanced squamous and&#xD;
      nonsquamous NSCLC leading to an increase of the 1-year OS rate of approximately 10-15% in&#xD;
      both histologies. Nivolumab, pembrolizumab and atezolizumab are now considered a standard of&#xD;
      care in 2nd line advanced NSCLC and in 1st line for pembrolizumab but but prognosis still&#xD;
      remains poor in advanced NSCLC. Overall survival (OS) of patients with advanced (stage&#xD;
      III/IV) NSCLC remains limited with a median OS of 12.2 months in non-squamous NSCLC and 9.2&#xD;
      months in squamous NSCLC if anti-PD1 alone. It is of around 16 months if pembrolizumab is&#xD;
      combined with chemotherapy.&#xD;
&#xD;
      Preclinical data indicates that anti-tumor efficacy is increased when anti-PD-1/-L1 are&#xD;
      combined with irradiation (IR). Radiotherapy alone can elicit tumor cell death which can&#xD;
      increase tumor antigen in the blood stream, favoring recognition by the immune system and its&#xD;
      activation against tumor cells outside of the radiation field (=&quot;abscopal effect&quot;).&#xD;
&#xD;
      IR may also reverse acquired resistance to PD-1 blockade immunotherapy by limiting T-cell&#xD;
      exhaustion.&#xD;
&#xD;
      Because of these preclinical and clinical data several studies analysing the combination of&#xD;
      IR and anti-PD1 in NSCLC are ongoing. Among them, two studies are testing the administration&#xD;
      of IR and nivolumab in stage III NSCLC: the NCT02768558 phase III trial (RTOG), and the&#xD;
      NCT02434081 phase II trial (ETOP). Antonia et al [2017] tested the use of anti-PD-L1 after&#xD;
      chemoradiotherapy in unresectable stage III NSCLC. Median time to distant metastasis was&#xD;
      increased (23.2 months vs. 14.6 months, p&lt;0.001). An increase of OS is consequently expected.&#xD;
&#xD;
      However, no study involving concurrent RT and pembrolizumab combined with chemotherapy in&#xD;
      advanced NSCLC is ongoing, which is the purpose of the present study, NIRVANA-Lung.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">September 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival (OS) rate is defined as the time from randomization to the date of documented death from any cause or last follow-up.OS rate will be reported at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Tumour response is defined as the percentage of patients with a complete response (CR) or partial response (PR), according to RECIST 1.1 and iRECIST (centralized response evaluation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from randomization until documented disease progression (PD) according to RECIST 1.1 and iRECIST (centralized response evaluation for both arms), or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and distant controls in irradiated patients</measure>
    <time_frame>6 months and 1 years</time_frame>
    <description>Local and distant controls in irradiated patients are defined as the time from randomization to the first documented local event or distant event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patients using EORTC-QLQ-C 30</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute/Late toxicities</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Acute/ late toxicity will be assessed according to the flowchart and graded by CTCAE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-small lung cancer specific survival</measure>
    <time_frame>At 1 year and 2 years</time_frame>
    <description>To evaluate, compared to standard of care, whether the addition of radiotherapy improves survival of patients until death from non-small lung cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <condition>Non-Small Cell Carcinoma of Lung, TNM Stage 4</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+ Chemotherapy + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.&#xD;
Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.&#xD;
Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).&#xD;
Irradiated tumor size will be ≤5 cm (GTV &lt;65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+ Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Squamous-cell lung carcinoma:&#xD;
Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )&#xD;
Non squamous-cell lung carcinoma:&#xD;
Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)&#xD;
Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Irradiation technique (3D-CRT or SABR) will be at physician discretion.</description>
    <arm_group_label>Pembrolizumab+ Chemotherapy + Radiotherapy</arm_group_label>
    <other_name>3D-CRT or SABR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity</description>
    <arm_group_label>Pembrolizumab+ Chemotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab+ Chemotherapy + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity</description>
    <arm_group_label>Pembrolizumab+ Chemotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab+ Chemotherapy + Radiotherapy</arm_group_label>
    <other_name>Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Patient must have signed a written informed consent form prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Histologically or cytologically confirmed advanced (stage IIIB/IIIC/IV), squamous or&#xD;
             non-squamous NSCLC&#xD;
&#xD;
          3. NSCLC patients eligible for treatment with pembrolizumab and chemotherapy according to&#xD;
             the European Marketing Authorization:&#xD;
&#xD;
               1. squamous: in combination with carboplatin and either paclitaxel or nab-paclitaxel&#xD;
&#xD;
               2. non squamous with no EGFR or ALK positive mutations: in combination with&#xD;
                  pemetrexed and a platinum based chemotherapy&#xD;
&#xD;
          4. Patient ≥18 of age&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1&#xD;
&#xD;
          6. Life expectancy &gt;3 months&#xD;
&#xD;
          7. Measurable lesion as assessed by RECIST version 1.1&#xD;
&#xD;
          8. Metastases and/or primary tumour eligible for 3 dimensional conventional radiotherapy&#xD;
             (3D-CRT) or stereotactic ablative radiotherapy (SABR) in terms of dose constraints at&#xD;
             organ at risk (according to QUANTEC review)&#xD;
&#xD;
          9. Patients must have adequate organ function defined by the following laboratory results&#xD;
             obtained within 14 days prior to the first study treatment:&#xD;
&#xD;
               1. absolute neutrophil count of ≥1 500 /mm³&#xD;
&#xD;
               2. platelets ≥ 100 000/mm³&#xD;
&#xD;
               3. haemoglobin &gt;9 g/dL (transfusions allowed)&#xD;
&#xD;
               4. creatinine clearance &gt;60 mL/min&#xD;
&#xD;
               5. bilirubin ≤1.5 X upper limit of normal (ULN) (unless Gilbert's syndrome where 3 X&#xD;
                  ULN is permitted)&#xD;
&#xD;
               6. serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 X&#xD;
                  ULN (unless documented liver metastasis where ≤5 X ULN is permitted)&#xD;
&#xD;
               7. Alkaline phosphatase (ALP) ≤2.5 X ULN (unless documented bone or liver metastasis&#xD;
                  where ≤5 X ULN is permitted)&#xD;
&#xD;
               8. International normalized ratio (INR), prothrombin (PT), and prothrombin time&#xD;
                  (PTT) ≤1.5 X ULN (unless the subject is receiving anticoagulant therapy)&#xD;
&#xD;
         10. Woman of childbearing potential and male patients must agree to use adequate&#xD;
             contraception for the duration of study participation and up to 6 months after&#xD;
             completing treatment/therapy&#xD;
&#xD;
         11. Patients affiliated to the social security system (or equivalent)&#xD;
&#xD;
         12. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits, and examinations including&#xD;
             follow-up&#xD;
&#xD;
        NON-INCLUSION CRITERIA:&#xD;
&#xD;
          1. Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK&#xD;
             translocation Note: documentation of these mutation for non-squamous histology is&#xD;
             mandatory as standard of care&#xD;
&#xD;
          2. Stage IIIB/IIIC NSCLC patient eligible to curative (thoracic radiotherapy or surgery)&#xD;
             treatments in first line treatment&#xD;
&#xD;
          3. Prior therapy with T-cell costimulation or checkpoint-targeted agents Note: Stage&#xD;
             I-III NSCLC who previously received single-agent anti-PD(L)1 immunotherapy and&#xD;
             ultimately develop metastases remain eligible (minimal immunotherapy washout period of&#xD;
             3 months)&#xD;
&#xD;
          4. Clinical need of radiotherapy (e.g.: whole brain irradiation, painful metastasis,&#xD;
             bleeding, compressive metastases)&#xD;
&#xD;
          5. Irradiation within 2 months before inclusion&#xD;
&#xD;
          6. Leptomeningeal carcinomatosis, or metastases with indistinct borders making targeting&#xD;
             not feasible&#xD;
&#xD;
          7. Patient with evidence of active (presence of symptoms or requiring steroid treatment)&#xD;
             central nervous system (CNS) metastases and/or carcinomatous meningitis. Patient with&#xD;
             brain metastasis can be included if asymptomatic and not requiring steroids&#xD;
&#xD;
          8. Metastases located within 3 cm of the previously irradiated structures (EQD2doses):&#xD;
&#xD;
               1. Spinal cord previously irradiated to &gt;40 Gy;&#xD;
&#xD;
               2. Brachial plexus previously irradiated to &gt;50 Gy;&#xD;
&#xD;
               3. Small intestine, large intestine, or stomach previously irradiated to &gt;45 Gy;&#xD;
&#xD;
               4. Brainstem previously irradiated to &gt;50 Gy;&#xD;
&#xD;
               5. Lung previously irradiated with prior V20Gy &gt;30%&#xD;
&#xD;
          9. Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized&#xD;
             with hormonal substitution, psoriasis&#xD;
&#xD;
         10. Symptomatic interstitial lung disease&#xD;
&#xD;
         11. Systemic immunosuppression or systemic immunosuppressive medicinal products within 2&#xD;
             weeks prior to study entry&#xD;
&#xD;
         12. Concomitant treatment with steroids &gt; 10 mg Note1: higher dose of steroids can be&#xD;
             prescribed in case of occurrence of toxicities during radiotherapy; prophylactic dose&#xD;
             of maximum 1 mg per kg during 2 weeks are authorized during the delivery of more than&#xD;
             6 Gy per fraction Note2: temporary use of steroid (less than 4 weeks) at a dose of 1&#xD;
             mg/kg is accepted&#xD;
&#xD;
         13. Prior invasive malignancy within the past 2 years (except non-melanomatous skin cancer&#xD;
             non-invasive carcinoma in-situ of the breast, oral cavity, bladder or cervix)&#xD;
&#xD;
         14. Known Acquired Immune Deficiency Syndrome (AIDS) or severe uncontrolled co-morbidity&#xD;
&#xD;
         15. Known currently active infection including hepatitis B and hepatitis C&#xD;
&#xD;
         16. Patient who was administered a live, attenuated vaccine within 28 days prior to&#xD;
             enrolment&#xD;
&#xD;
         17. Patient with any other disease or illness that requires hospitalisation or is&#xD;
             incompatible with the study treatment are not eligible. Patient unable to comply with&#xD;
             study obligations for geographic, social, or physical reasons, or who is unable to&#xD;
             understand the purpose and procedures of the study&#xD;
&#xD;
         18. Patient who have taken any investigational medicinal product or have used an&#xD;
             investigational device within 30 days of inclusion&#xD;
&#xD;
         19. Pregnant or breast feeding woman&#xD;
&#xD;
         20. Person deprived of their liberty or under protective custody or guardianship&#xD;
&#xD;
         21. If pemetrexed: patient is unable or unwilling to take folic acid or vitamin B12&#xD;
             supplementation&#xD;
&#xD;
         22. Pre-existing peripheral neuropathy of a severity of grade ≥ 2 by NCI CTCAE v5.0&#xD;
&#xD;
         23. Known hypersensitivity to one of the compounds or substances used in this protocol&#xD;
&#xD;
         24. Major surgery within the 28 days before initiating study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme DOYEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonin LEVY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin BESSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie BERGEAUD, PhD</last_name>
    <phone>+33 1 73 77 54 38</phone>
    <email>m-bergeaud@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Assia LAMRANI-GHAOUTI, PhD</last_name>
    <email>a-lamrani-ghaouti@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre TREMOLIERES, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas POUREL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie COUSIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radj GERVAIS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire De Caen - Hôpital Cote De Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Dr Jean-Eric TECHER</name>
      <address>
        <city>Calais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima MENIAI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Cannes Simone Veil</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick DUVAL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pôle départemental de Cancérologie Libérale 37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas BOISSERIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale DUBRAY LONGERAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal De Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MONNET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie LAGRANGE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas LESCUT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei SEFERIAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Chenieux</name>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ZASADNY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de cancérologie du grand Montpellier-Clinique Clementville</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BEGUIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DOYEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Hôpital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles NALTET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MEILLAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor RIVIN DEL CAMPO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain PREVOST, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle OTZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland SCHOTT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey RABEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan KHALIFA, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT DUCHENE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonin LEVY, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>July 25, 2022</last_update_submitted>
  <last_update_submitted_qc>July 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD(L)-1 blockage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03774732
org study id: UC-0107/1718
nct id: NCT03774732
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
is us export: No
Overall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer
      (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in
      non squamous NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death
      1/ligand 1 (PD-1/-L1) were targeted with nivolumab (IgG4) in advanced squamous and
      nonsquamous NSCLC leading to an increase of the 1-year OS rate of approximately 10-15% in
      both histologies. Nivolumab, pembrolizumab and atezolizumab are now considered a standard of
      care in 2nd line advanced NSCLC and in 1st line for pembrolizumab but but prognosis still
      remains poor in advanced NSCLC. Overall survival (OS) of patients with advanced (stage
      III/IV) NSCLC remains limited with a median OS of 12.2 months in non-squamous NSCLC and 9.2
      months in squamous NSCLC if anti-PD1 alone. It is of around 16 months if pembrolizumab is
      combined with chemotherapy.

      Preclinical data indicates that anti-tumor efficacy is increased when anti-PD-1/-L1 are
      combined with irradiation (IR). Radiotherapy alone can elicit tumor cell death which can
      increase tumor antigen in the blood stream, favoring recognition by the immune system and its
      activation against tumor cells outside of the radiation field (="abscopal effect").

      IR may also reverse acquired resistance to PD-1 blockade immunotherapy by limiting T-cell
      exhaustion.

      Because of these preclinical and clinical data several studies analysing the combination of
      IR and anti-PD1 in NSCLC are ongoing. Among them, two studies are testing the administration
      of IR and nivolumab in stage III NSCLC: the NCT02768558 phase III trial (RTOG), and the
      NCT02434081 phase II trial (ETOP). Antonia et al [2017] tested the use of anti-PD-L1 after
      chemoradiotherapy in unresectable stage III NSCLC. Median time to distant metastasis was
      increased (23.2 months vs. 14.6 months, p<0.001). An increase of OS is consequently expected.

      However, no study involving concurrent RT and pembrolizumab combined with chemotherapy in
      advanced NSCLC is ongoing, which is the purpose of the present study, NIRVANA-Lung.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Overall Survival
time frame: 2 years
description: Overall Survival (OS) rate is defined as the time from randomization to the date of documented death from any cause or last follow-up.OS rate will be reported at 2 years
measure: Tumour response
time frame: 1 and 2 years
description: Tumour response is defined as the percentage of patients with a complete response (CR) or partial response (PR), according to RECIST 1.1 and iRECIST (centralized response evaluation).
measure: Progression-free survival
time frame: 1 and 2 years
description: Progression-free survival (PFS) is defined as the time from randomization until documented disease progression (PD) according to RECIST 1.1 and iRECIST (centralized response evaluation for both arms), or death, whichever occurs first.
measure: Local and distant controls in irradiated patients
time frame: 6 months and 1 years
description: Local and distant controls in irradiated patients are defined as the time from randomization to the first documented local event or distant event.
measure: Quality of life of the patients using EORTC-QLQ-C 30
time frame: up to 2 years
description: Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life
measure: Acute/Late toxicities
time frame: up to 2 years
description: Acute/ late toxicity will be assessed according to the flowchart and graded by CTCAE v5
measure: Non-small lung cancer specific survival
time frame: At 1 year and 2 years
description: To evaluate, compared to standard of care, whether the addition of radiotherapy improves survival of patients until death from non-small lung cancer
arm group label: Pembrolizumab+ Chemotherapy + Radiotherapy
arm group type: Experimental
description: In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.
Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.
Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).
Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints.
arm group label: Pembrolizumab+ Chemotherapy
arm group type: Active Comparator
description: Squamous-cell lung carcinoma:
Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )
Non squamous-cell lung carcinoma:
Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)
Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status.
intervention type: Radiation
intervention name: Radiotherapy
description: Irradiation technique (3D-CRT or SABR) will be at physician discretion.
arm group label: Pembrolizumab+ Chemotherapy + Radiotherapy
other name: 3D-CRT or SABR
intervention type: Drug
intervention name: Pembrolizumab
description: pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
arm group label: Pembrolizumab+ Chemotherapy
arm group label: Pembrolizumab+ Chemotherapy + Radiotherapy
intervention type: Drug
intervention name: Chemotherapy
description: for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
arm group label: Pembrolizumab+ Chemotherapy
arm group label: Pembrolizumab+ Chemotherapy + Radiotherapy
other name: Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jérôme DOYEN, MD
role: Principal Investigator
affiliation: Centre Antoine Lacassagne
last name: Antonin LEVY, MD
role: Principal Investigator
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
last name: Benjamin BESSE, MD
role: Principal Investigator
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
last name: Marie BERGEAUD, PhD
phone: +33 1 73 77 54 38
email: m-bergeaud@unicancer.fr
last name: Assia LAMRANI-GHAOUTI, PhD
email: a-lamrani-ghaouti@unicancer.fr
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: France
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Paclitaxel
mesh term: Cisplatin
mesh term: Carboplatin
mesh term: Pembrolizumab
mesh term: Pemetrexed